Open AccessCURRENT UPDATES ON COVID-19 VACCINES
Author(s) -
Shashi Kiran Misra,
Kamla Pathak,
Devender Pathak,
Ramakant Yadav
Publication year - 2021
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2021.v14i5.41061
Subject(s) - pandemic , covid-19 , medicine , clinical trial , outbreak , business , virology , disease , infectious disease (medical specialty) , pathology
Background: COVID-19 caused the world to shut down and made us to critically look out at our advanced healthcare systems that are well prepared for heart diseases, cancers, organ transplantation but not for attack of a tiny virus. WHO and other authorized bodies are continuously issuing advisory on preventive measurements, tracking the outbreak and distributing vital medical kits. Scientific community and vaccine experts have developed and started to distribute safe and effective immunization worldwide.
Objective: The paper outlines several developed and developing immunization vehicles for the management of COVID -19 that will hit global market in year 2021.
Method: Non clinical and clinical data are collected from authentic sources of World Health Organization portal and press release provided by COVID-19 vaccine developers.
Result: Different platforms including mRNA, DNA, Viral vectors, Synthetic peptides etc. have been conversed that are globally involved for elimination of SARS-CoV-2, a causative virus of COVID-19.
Conclusion: Numerous academic institutions and companies of worldwide have developed and evaluated their inoculums after extremely compressed clinical trial agendas. Worldwide eminent developers such as Pfizer and BioNTech, Moderna, AstraZenaca and Bharat Biotech are ready with their esteemed products for the management of pandemic COVID-19. They explored pharmaceutical technologies reliant on genetics, nanoengineering and biotechnology for successful development of these anti SARS-CoV-2 inoculums. Taking account on conditions of more vulnerable community including immunocompromised, geriatrics and comorbidities patients the safety and efficacy of vaccine are yet to be monitored..